Advertisement
IMCC vs SCYX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMCC is a StrongBuy and SCYX is a Hold.
IMCC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IMCC turned positive on September 25, 2026. Looking at past instances where IMCC's MACD turned positive, the stock continued to rise in 33 of 37 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 161 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
IMCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMCC as a result. In 84 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMCC entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.101) is normal, around the industry mean (10.407). P/E Ratio (-0.009) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
SCYX in downward trend: price dove below 50-day moving average on October 06, 2026
SCYX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In 63 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for SCYX turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 34 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for SCYX crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
SCYX broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SCYX entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SCYX's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +15.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in 193 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.566) is normal, around the industry mean (10.407). P/E Ratio (-4.187) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1.647) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
IMCC | SCYX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 95 | |
PRICE GROWTH RATING 1..100 | 97 | 79 | |
P/E GROWTH RATING 1..100 | 100 | 37 | |
SEASONALITY SCORE 1..100 | 45 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SCYX's Valuation (21) in the Pharmaceuticals Other industry is in the same range as IMCC (26) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.
SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as IMCC (100) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.
SCYX's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as IMCC (100) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.
SCYX's Price Growth Rating (79) in the Pharmaceuticals Other industry is in the same range as IMCC (97) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.
SCYX's P/E Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMCC (100) in the null industry. This means that SCYX’s stock grew somewhat faster than IMCC’s over the last 12 months.
| IMCC | SCYX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Advances ODDS (%) | 4 days ago 84% | 22 days ago 84% |
| Declines ODDS (%) | 1 day ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMCC’s FA Score shows that 1 FA rating(s) are green while SCYX’s FA Score has 1 green FA rating(s).
- IMCC’s FA Score: 1 green, 4 red.
- SCYX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMCC’s TA Score shows that 3 TA indicator(s) are bullish while SCYX’s TA Score has 3 bullish TA indicator(s).
- IMCC’s TA Score: 3 bullish, 4 bearish.
- SCYX’s TA Score: 3 bullish, 7 bearish.
Price Growth
IMCC (@Pharmaceuticals: Generic) experienced а -11.85% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was -4.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
IMCC is expected to report earnings on Nov 12, 2026.
SCYX is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
IMCC and
Correlation & Price change
A.I.dvisor tells us that IMCC and TXMD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMCC and TXMD's prices will move in lockstep.
| Ticker / NAME | Correlation To IMCC | 1D Price Change % | ||
|---|---|---|---|---|
| IMCC | 100% | -22.29% | ||
| TXMD - IMCC | 25% Poorly correlated | -2.63% | ||
| ACB - IMCC | 24% Poorly correlated | +0.25% | ||
| CTOR - IMCC | 23% Poorly correlated | -0.11% | ||
| SCYX - IMCC | 22% Poorly correlated | +0.66% | ||
| SNDL - IMCC | 22% Poorly correlated | +0.78% | ||
More | ||||
SCYX and
Correlation & Price change
A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.
| Ticker / NAME | Correlation To SCYX | 1D Price Change % | ||
|---|---|---|---|---|
| SCYX | 100% | +0.66% | ||
| ACET - SCYX | 27% Poorly correlated | -4.68% | ||
| ELAN - SCYX | 26% Poorly correlated | +0.62% | ||
| CRDL - SCYX | 24% Poorly correlated | -1.71% | ||
| IMCC - SCYX | 24% Poorly correlated | -22.29% | ||
| TXMD - SCYX | 23% Poorly correlated | -2.63% | ||
More | ||||